Safety scare cleared and early data in hand, Ultragenyx dishes out $75M to buy rare disease partner
It had its ups and downs, but Ultragenyx’s three-year-old partnership with an Angelman syndrome-focused biotech has culminated in a buyout.
With $75 million upfront, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
